RDHL

RedHill Biopharma Ltd Announces RedHill Biopharma Announces Last Patient Out

RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib

RedHill Biopharma's Movantik® Added as Unrestricted Preferred Brand To A Major National Commercial Formulary Serving over 30 Million Americans

RedHill Biopharma reports preliminary results from new preclinical study showing potent inhibition of COVID-19 variants by opaganib

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study

RedHill Biopharma presents positive Phase 2 data for oral opaganib in hospitalized patients with COVID-19 at World Microbe Forum